Registers 729.6M Shares for Resale from Highly Dilutive Convertible Note

summarizeSummary

CERO Therapeutics filed a prospectus supplement to register 729.6 million shares of common stock for resale, stemming from a highly dilutive convertible promissory note previously disclosed.

check_boxKey Events

• Registers Massive Share Volume

  The company registered 729,596,950 shares of common stock for resale, which will facilitate significant dilution.

• Follows Dilutive Convertible Note Issuance

  This registration directly relates to a convertible promissory note issued on April 8, 2026, for a purchase price of $350,000 with a principal face value of $437,500, as detailed in a concurrent 8-K filing.

• Highly Unfavorable Conversion Terms

  The note is convertible at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices over 20 days, indicating a 'death spiral' financing structure.

• Ongoing Dilution Pattern

  This is the seventh prospectus supplement related to the underlying registration statement, highlighting a continuous pattern of capital raises through dilutive instruments.

auto_awesomeAnalysis

This prospectus supplement registers a massive number of shares (729.6 million) for resale, directly enabling the dilution from the convertible promissory note disclosed in the concurrent 8-K. The terms of the note, including a conversion price at a significant discount to market and based on the lowest trading prices, are extremely unfavorable and indicate severe financial distress. The sheer volume of shares registered for resale, representing a value far exceeding the company's current market capitalization, signals a substantial and ongoing dilutive event that will heavily impact existing shareholders.